A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test

• Vanda Pharmaceuticals Inc (NASDAQ: VNDA) announced the results from its Phase 3 study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant effectively prevents vomiting associated with motion sickness.

• The Phase 3 study was conducted in real-world conditions on boats in the coastal waters of the U.S.

• Also Read: Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug.

• In the Motion Syros study, 365 participants embarked on boat trips under varied sea conditions and received tradipitant 170 mg, tradipitant 85 mg, or placebo.

• Study participants had a prior history of motion sickness and were distributed across thirty-four boat trips between November 2021-April 2023.

• 170 mg and 85 mg tradipitant doses were superior to placebo in preventing vomiting, with only 18.3% and 19.5% of participants experiencing vomiting on tradipitant 170 mg and 85 mg, respectively, compared to 44.3% of participants on placebo.

• The FDA has not approved a new medication for motion sickness in over forty years since scopolamine, a transdermal patch placed behind the ear, was approved in 1979.

• Price Action: VNDA shares are down 1.39% at $6.03 on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.